Clinical trials: Multiple Dose
Healthy Participants
A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants
1. Learn about the safety and tolerability of CK-3828136 after a single dose and multiple doses in healthy subjects. 2. Find out how much CK-3828136 is in the blood after a single dose and multiple doses. 3.
- Trial name
- NCT05662215
- Testing
- CK-3828136
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Cytokinetics
Hepatitis B, Chronic Hepatitis B
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B, Chronic Hepatitis B, Hepatitis B, Chronic, Hepatitis B Infection
- Trial name
- NCT02826018
- Testing
- ALN-HBV, Sterile Normal Saline (0.9% NaCl)
- Where
- 9 sites in Australia, Hong Kong and 4 more
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Healthy
A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People
This is a phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of 4 different oral formulations of LEO 32731 in healthy subjects. The trial will be conducted in 3 parts at a single site.
- Trial name
- NCT03812198
- Testing
- LEO 32731 modified release tablet, LEO 32731 blend, hard capsule, LEO 32731 API, hard capsule
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Healthy
A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects
The objectives of this study are: Stage 1: To assess the safety, tolerability, pharmacokinetic (PK) profile and pharmacodynamic (PD) effects of a range of doses of IW-1701 tablets administered orally to healthy subjects over 7…
- Trial name
- NCT02792998
- Testing
- IW-1701
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Cyclerion Therapeutics
Alzheimer Disease
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
BnH-015B is a small molecule compound that targets the GluN2B binding site on NMDA receptors and positively modulates. BnH-015B has shown, through nonclinical trials, to improve symptoms of cognitive decline by regulating the…
- Trial name
- NCT06535308
- Testing
- BnH-015B 5 mg, BnH-015B 10 mg, BnH-015B 20 mg
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- BnH Research
Healthy Volunteers
Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects
This study is designed to evaluate the potential effect of administration of tradipitant on CYP3A4 using midazolam pharmacokinetics as markers. The study will also further characterize the pharmacokinetics of tradipitant.
- Trial name
- NCT02621385
- Testing
- tradipitant, Midazolam
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Hiv
Pharmacokinetics and Safety of DolutegravIr in Neonate
A Phase I/II, open-label, single arm, two-stage trial to evaluate the single and multi-dose PK and safety of DTG in HIV-exposed neonates on ARV prophylaxis.
- Trial name
- PETITE-DTG (NCT05590325)
- Testing
- Dolutegravir
- Where
- South Africa
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Desmond Tutu TB Centre
Type2 Diabetes Mellitus
Continuous Multiple Dose PB-119 Injection in Health Volunteers
This is an open label, multiple dose study, pharmacokinetic and pharmacodynamics studies will be performed at the same time with tolerability study.
- Trial name
- NCT03062774
- Testing
- PB-119 injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- PegBio Co., Ltd.
Healthy Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese…
- Trial name
- NCT06144697
- Testing
- BMS-986465, Pegasys, Famotidine
- Where
- 2 sites in United States
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers
The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS AGT-LRx in up to 82 Healthy Volunteers
- Trial name
- NCT03101878
- Testing
- Ionis AGT-LRx
- Where
- Canada
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypophosphatasia (HPP)
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
This is a phase 1/2a randomised, placebo controlled, double-blind study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALE1 on healthy adult subjects and adult patients with Hypophosphatasia…
- Trial name
- NCT07179640
- Testing
- ALE1
- Where
- 3 sites in Germany, New Zealand and 1 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Alesta Therapeutics
Systemic Lupus Erythematosus, Healthy
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
The purpose of this study is to assess the safety and tolerability of JNJ-55920839 following single ascending intravenous (IV) dose administration in healthy participants and a single subcutaneous dose in healthy participants and…
- Trial name
- NCT02609789
- Testing
- JNJ-55920839
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Allergic Rhinitis, Upper Respiratory Infection
Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children
The primary goal of this study is to characterize the pharmacokinetics of doxylamine succinate in children ages 2 to < 18 years.
- Trial name
- NCT00796315
- Testing
- Doxylamine Succinate USP
- Where
- 6 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Healthy
A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects
This is a single and multiple ascending dose study in healthy male and female (of non-child bearing potential) Japanese and White volunteers, to assess the safety, tolerability, and blood and urine drug levels of FosD.
- Trial name
- NCT01167868
- Testing
- FosD
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety
This study aims to evaluate the effects of iclepertin in the range of therapeutic to supra-therapeutic exposures on the (QT/QTc): Electrocardiogram (ECG) time interval from the start of the QRS complex (ECG time interval) to the…
- Trial name
- NCT06070597
- Testing
- Iclepertin, Moxifloxacin
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029
This is a multiple dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational new drug.
- Trial name
- NCT00563810
- Testing
- MYO-029
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy
A Study of Baricitinib (LY3009104) in Healthy Chinese Participants
The main purpose of this study is to investigate the safety and tolerability of the study drug known as baricitinib in healthy Chinese participants.
- Trial name
- NCT02758613
- Testing
- Baricitinib
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
To Evaluate the PK, PD, Safety and Drug Tolerance in Healthy Volunteers
1. To evaluate the pharmacokinetic and pharmacodynamics characteristics after administration of Reference Drug or Test Drug in healthy volunteers under fasting conditions 2.
- Trial name
- NCT05433844
- Testing
- Reference Drug or Test Drug
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Healthy Subjects, Cystic Fibrosis
A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
This Phase 1/2a study is a double-blinded (subject and Investigator), randomized, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple…
- Trial name
- NCT03647228
- Testing
- IONIS-ENaCRx
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers
This is a dose block-randomized, double-blind, placebo- and active-controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of…
- Trial name
- NCT02757144
- Testing
- DWP14012, Esomeprazole
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.